Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Verastem (VSTM) Research & Development (2018 - 2025)

Verastem has reported Research & Development over the past 8 years, most recently at $31.7 million for Q4 2025.

  • Quarterly results put Research & Development at $31.7 million for Q4 2025, up 52.2% from a year ago — trailing twelve months through Dec 2025 was $114.6 million (up 40.9% YoY), and the annual figure for FY2025 was $114.6 million, up 40.9%.
  • Research & Development for Q4 2025 was $31.7 million at Verastem, up from $29.0 million in the prior quarter.
  • Over the last five years, Research & Development for VSTM hit a ceiling of $31.7 million in Q4 2025 and a floor of $8.9 million in Q1 2021.
  • Median Research & Development over the past 5 years was $14.4 million (2022), compared with a mean of $17.4 million.
  • Biggest five-year swings in Research & Development: decreased 18.56% in 2021 and later skyrocketed 109.52% in 2023.
  • Verastem's Research & Development stood at $11.4 million in 2021, then fell by 5.76% to $10.7 million in 2022, then skyrocketed by 109.52% to $22.5 million in 2023, then decreased by 7.51% to $20.8 million in 2024, then soared by 52.2% to $31.7 million in 2025.
  • The last three reported values for Research & Development were $31.7 million (Q4 2025), $29.0 million (Q3 2025), and $24.8 million (Q2 2025) per Business Quant data.